Ridgepost Capital Announces Retirement of Mark Hood as EVP and CAO DALLAS, March 23, 2026 (GLOBE NEWSWIRE) -- (NYSE: RPC) (“Ridgepost Capital” or the “Company”), a leading private markets solutions provider, today announced that Mark Hood will retire from his position as Executive Vice President and Chief Administration Officer, effective May 31, 2026. Mr. Hood will continue to serve the Company as a strategic advisor. “Since joining Ridgepost Capital prior to our October 2021 IPO, Mark has played a central role in building and scaling our firm,” said Luke Sarsfield, Ridgepost Capital C...
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company’s new Chief Financial Officer pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The ...
Enhanced Capital Named to the ImpactAssets 50 2026, the Definitive Guide to Impact Investing Fund Managers NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- (NYSE: RPC) (“Ridgepost Capital”), a leading private markets solutions provider, and (“Enhanced Capital”), a private credit strategy of Ridgepost Capital, today announced that Enhanced Capital has been selected to the , the definitive guide to impact investing fund managers globally. Now in its 15th year, the IA 50 highlights experienced and emerging fund managers committed to delivering measurable impact alongside financial returns. The...
Following the attack on Iran by the US and Israel late last month which targeted key military sites and strategic infrastructure, as well as a retaliation by Iran, there have been structural shifts in the oil & gas and energy markets. In this report, we discuss the effects of these structural shifts, as well as the impact of the conflict on global supply chains and our coverage universe.
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million Companies Resolve Lawsuit in Delaware BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra’s serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for $50 million. "We are pleased to have reached a mutually beneficial agreement with Commave regardin...
Zevra Reports Fourth Quarter and Full Year 2025 Financial Results Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted Company to host conference call and webcast TODAY, March 9, 2026, at 4:30 p.m. ET BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its f...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.